RPRX
NASDAQRoyalty Pharma plc
Website
News25/Ratings12
News · 26 weeks76+43%
2025-10-262026-04-19
Mix3190d
- Insider12(39%)
- Other6(19%)
- SEC Filings5(16%)
- Leadership3(10%)
- Earnings2(6%)
- M&A2(6%)
- Other1(3%)
Latest news
25 items- PRRoyalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field's most prominent awards. "Royalty Pharma believes that scientific
- PRRoyalty Pharma Declares Second Quarter 2026 DividendNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Roya
- PRRoyalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is th
- SECSEC Form 8-K filed by Royalty Pharma plc8-K - Royalty Pharma plc (0001802768) (Filer)
- SECSEC Form DEFA14A filed by Royalty Pharma plcDEFA14A - Royalty Pharma plc (0001802768) (Filer)
- SECSEC Form DEF 14A filed by Royalty Pharma plcDEF 14A - Royalty Pharma plc (0001802768) (Filer)
- INSIDERSEC Form 4 filed by Coyne Terrance P.4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 13F-NT filed by Royalty Pharma plc13F-NT - Royalty Pharma plc (0001802768) (Filer)
- INSIDERSEC Form 4 filed by Bassler Bonnie L4 - Royalty Pharma plc (0001802768) (Issuer)
- PRRoyalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated DiseasesNEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases. "We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804," said Pablo Legorreta, Chief Executive Officer and Chairman of the
- INSIDERSEC Form 4 filed by Coyne Terrance P.4 - Royalty Pharma plc (0001802768) (Issuer)
- PRRoyalty Pharma Appoints Lucas Glass as Head of Artificial IntelligenceNEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. "Lucas's appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners. Luc
- PRRoyalty Pharma Announces Expansion of Leadership TeamNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. "We are thrilled that Greg will join Royalty Pharma and strengthen our leadership team," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Greg brings tremendous experience advising healthcare companies on capital raising, strategy, and mergers and acquisitions and he will be a critical addition t
- INSIDEREVP & CFO Coyne Terrance P. sold $1,627,534 worth of Class A Ordinary Shares (34,791 units at $46.78) (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- PRRoyalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global PlatformNEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the va
- PRRoyalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note FinancingZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zymeworks Inc. (NASDAQ:ZYME) today announced an agre
- PRZymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agre
- PRRoyalty Pharma to Present at TD Cowen's 46th Annual Health Care ConferenceNEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and m
- INSIDEREVP & CFO Coyne Terrance P. sold $1,576,606 worth of Class A Ordinary Shares (34,791 units at $45.32) (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plcSCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)
- INSIDERCEO, Chairman of the Board Legorreta Pablo G. was granted 157,828 units of Class A Ordinary Shares, increasing direct ownership by 17% to 1,098,783 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & CFO Coyne Terrance P. was granted 26,626 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP & Vice Chairman Hite Christopher was granted 26,626 units of Class A Ordinary Shares (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- INSIDEREVP, Research & Investments Urist Marshall was granted 19,970 units of Class A Ordinary Shares, increasing direct ownership by 270% to 27,368 units (SEC Form 4)4 - Royalty Pharma plc (0001802768) (Issuer)
- SECSEC Form 10-K filed by Royalty Pharma plc10-K - Royalty Pharma plc (0001802768) (Filer)